BiomÃ©rieux

History

Year	Detail
1963	Establishment of BD Mérieux.
1967	BD Mérieux launched a fibrometer.
1969	The company has launched its first toxoplasmosis detection kit and miniaturized API 20E strip.
1972	The company has started the production and sales of ready-to-use culture media in Petri plates.
1974	Alain Mérieux controled BD Mérieux, which later on becomes bioMérieux.
	The company has launched Slidex Meningitis kit.
1986	The company acquired Api Systems.
1988	Biomerieux acquired Vitek Systems, one of the major player in automated bacterial identification.
1990	The company acquired BOOM extraction and NASBA amplification technologies for molecular diagnostics.
1991	The company launched VIDAS with having 8 initial kits.
1992	VIDAS automated immunoassay platform has been adapted for industrial applications.
1997	The company has launched BacT/ALERT 3D and VITEK 2.
2001	The company acquired OrganonTeknika.
2004	The bioMérieux has been listed on the stock exchange.
	The company has launched TEMPO and VITEK 2 Compact.
2006	The company has acquired Bacterial Barcodes (U.S.).
2007	Biomerieux acquired Biomedics, a manufacturer of culture media and BTF, an industrial microbiology specialist.
2008	Biomerieux acquired AB BIODISK (Sweden).
	The company acquired AviaraDx, which was formerly bioTheranostics, a specialist in the molecular diagnosis of tumorous tissues.
	The company acquired PML Microbiologicals, who engaged in the development of culture media.
	Joint venture with Sysmex, the Japanese market leader in the field of in vitro diagnostics.
	Biomerieux collaborated with Shanghai Kehua Bio-engineering for the development of microplate immunoassays.
2010	The company acquiredd Meikang Biotech and Shanghai Zenka Biotechnology.
	The company acquired Meikang Biotech.
	The company acquired Shanghai Zenka Biotechnology.
2011	The company acquired ARGENE, a molecular biology specialist.
	The company acquired AES Laboratoire.
2012	The company has acquired RAS (India) and made an partnership with Quanterix.
2013	The FDA has approved the novel molecular test THxID-BRAF.
2014	The FDA gave clearance for the FilmArray Gastrointestinal (GI) Panel.
	The company acquired BioFire Diagnostics Inc.
2015	Biomerieux launched bioMérieux EPISEQ.
	The company has launched GENE-UP A, an advanced PCR system used for agri-food sector customers.
2016	The company has moving its headquarters to the Campus de l'Étoile.
	Acquistion of Hyglos will brings BioMérieux an unique expertise in the development of recombinant proteins used for detecting endotoxins in pharmaceutical products.
2017	The company has got the FDA clearance for RAPIDEC CARBA NP test.
2018	The company has acquired Astute Medical.
2019	Acquistion of Invisible Sentinel will allow Biomerieux to use user-friendly molecular diagnostic tools for quick, accurate, and reliable detection of pathogens and spoilage organisms in foods and beverages.
2020	The US Food and Drug Administration (FDA) has provided authorization for emergency use of the BIOFIRE COVID-19 test to detect SARS-CoV-2.
	The company has launched BIOFIRE MYCOPLASMA Molecular biology test for the detection of mycoplasma.
2021	The company has made a co-exclusive distribution agreement with Specific Diagnostics.